Drug Interaction Study Between Dorzagliatin and Empagliflozin

Study Overview
=================
Brief Summary
-----------------
This is a Phase 1, open-label, sequential, multiple-dose, drug interaction study of glucokinase activator dorzagliatin and empagliflozin in subjects with T2DM. Pharmacokinetics and pharmacodynamics when dorzagliatin and empagliflozin given alone and in combination will be studied.

Official Title
-----------------
A Phase 1, Open-Label, Sequential, Multiple-Dose, Drug-Drug Interaction Study of Dorzagliatin and Empagliflozin in Subjects With Type 2 Diabetes Mellitus

Conditions
-----------------
Patients

Intervention / Treatment
-----------------
* Drug: Empagliflozin
* Drug: Dorzagliatin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects diagnosed with T2DM within at least 3 months prior to screening Male and/or female subjects between the ages of 30 and 65 years, inclusive; Body Mass Index (BMI) of 19 to 38 kg/m2, inclusive, at screening; Fasting C-peptide test result >0.3 nmol/L (>0.90 ng/mL); HbA1c ≥7% and ≤10.5%; Exclusion Criteria: Fasting blood glucose at screening or Day -1 ≤110 or ≥270 mg/dL ; Type 1 diabetes mellitus; Reported incidence of severe hypoglycemia within 3 months prior to screening; Known contraindications to empagliflozin; Clinically significant gastrointestinal disorder; History or symptoms of clinically significant cardiovascular disease; History of more than three urinary tract infections and/or more than three genital fungal infections in the last 12 months; Reported history of clinically significant central nervous system disease including within one year prior to screening; Reported history of liver disease; Reported history of clinically significant renal disease; Estimated glomerular filtration rate (eGFR) ≤60 mL/min/1.73m2; Acute or chronic metabolic acidosis, including diabetic ketoacidosis; Known or suspected malignancy; Any reported hypersensitivity or intolerance to empagliflozin; Antidiabetic treatment with insulin, sulfonylureas, thiazolidinediones or GLP-1 agonist within 3 months prior to screening; Systolic blood pressure <90 or >160 mmHg or diastolic blood pressure <60 or >100 mmHg at screening; A hospital admission or major surgery within 90 days prior to screening; Uncontrolled hypertriglyceridemia >500 mg/dL; Positive blood screen for HIV, HBsAg, or hepatitis C antibody; Positive pregnancy test result; Treated with any investigational drugs within 6 weeks prior to screening; Reported history of prescription drug abuse; Reported history of alcohol abuse Reported history of donation or acute loss of blood during the 90 days prior to screening;

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Sequential Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Sequential arm ABC<br>A: Empagliflozin 25 mg QD in the morning on Days 1-5; B: Empagliflozin 25 mg in the morning and Dorzagliatin 75 mg BID (morning and evening) on Days 6-10, with only the morning dose on Day 10; C: Dorzagliatin 75 mg BID (morning and evening) on Days 11-15, with only the morning dose on Day 15. | Drug: Empagliflozin<br>* Empagliflozin as Jardiance® 25 mg film-coated tablets for oral administration<br>* Other names: Jardiance;Drug: Dorzagliatin<br>* Glucokinase activator currently under development<br>* Other names: HMS5552;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cmax,ss | maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ | up to 5 days | 
| AUCτ,ss | area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ | up to 5 days |